Pacific Edge logo

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pacific Edge shares (PEB)

Learn how to easily invest in Pacific Edge shares on the NZX.

Pacific Edge specialises in developing cancer diagnostic tests to help with the detection and management of cancer. If you’d like to buy Pacific Edge shares (PEB) on New Zealand’s Exchange (NZX), we’ll show you how below.

How to buy shares in Pacific Edge on the New Zealand Exchange

  1. Compare share trading platforms. If you’re a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table. Most importantly, you need to find a share trading platform that allows you to trade on the NZX.
  2. Open and fund your share trading account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Pacific Edge. Find the stock by name or ticker symbol: PEB. Research its history to confirm it’s a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pacific Edge reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market’s ups and downs. You may be able to buy a fractional share of Pacific Edge, depending on your share trading account.
  6. Check in on your investment. Congratulations, you own a part of Pacific Edge. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Compare NZX share trading platforms

1 - 4 of 4
Name Product Min. Monthly Fee Available Asset Types Available Markets
BlackBull Markets Share Trading
Shares, ETFs
US, NZ, AU, Funds with exposure to multiple markets
Trade 23,000+ shares and access 80+ global markets across the US, New Zealand, Australia and more, plus benefit from extended trading hours, no monthly fees, 24/6 dedicated local support and a mobile trading app available on both Android and iOS.
Shares, ETFs, Managed Funds, Index Funds
US, NZ, AU, Funds with exposure to multiple markets
Trade and invest in more than 8,000 companies, ETFs and managed funds across New Zealand, the US and Australia.
ASB Securities
Shares, ETFs, Bonds
NZ, AU, Funds with exposure to multiple markets
Direct Broking
$5 per month
Shares, ETFs, Bonds
NZ, AU, Funds with exposure to multiple markets

Compare up to 4 providers

Pacific Edge overview and background

Founded in 2001, Pacific Edge is a cancer diagnostics company that specialises in discovering and developing diagnostic and prognostic tests to help detect and manage cancer.

Its current commercial focus is on bladder cancer products, including its Cxbladder cancer detection and management tests, but it has also filed patents for products and tools that target gastric, colorectal and endometrial cancers among others.

The company has laboratories in New Zealand and in the United States, and its headquarters are located in Dunedin.

Performance and company results

In its full year results, released May 2022, Pacific Edge Limited announced the following key results:

  • Total operating revenue of $11.4 million (an increase of 49%)
  • Total income of $13.9 million (an increase of 33%)
  • Net loss after tax increased to $19.8 million from $14.2 million over the same period a year ago.
  • Net operating expenses increased to $33.7 million from $24.7 million in the prior year.
  • Pacific Edge raised $103.5 million in capital in 2021.

Key details

NamePacific Edge LimitedIndustryDiagnostics & Research
Ticker symbolPEBISINNZPEBE0002S1
TypeOrdinary sharesDate listed on NZX07 Feb 2003
End of financial yearMarchChief executive officerDavid Gregory Darling
Disclaimer: This information should not be interpreted as an endorsement of stocks, ETFs or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Stocks and ETFs trading involves substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site